FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.’s Wishes
Why it matters: The FDA's reversal will allow compounding pharmacies to continue selling peptides, impacting consumers seeking health and longevity benefits.
- The FDA is anticipated to lift its 2023 restriction on peptides, allowing compounding pharmacies to resume sales.
- Peptides were previously removed from the agency's list of products available through compounding pharmacies.
- RFK Jr.'s wishes are being heeded by the FDA's expected reversal regarding peptide sales.
The FDA is poised to reverse its 2023 decision to restrict compounding pharmacies from selling peptides, a move that aligns with calls from figures like RFK Jr. These peptides are widely promoted for their potential longevity and health benefits, making the FDA's expected reversal a significant development for both consumers and the compounding pharmacy industry.
